Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database.

导出 LinkOut

翻译打印收藏纠错

作者： Emilie,Casarotto ^[1] ; Sheenu,Chandwani ^[2] ; Laurent,Mortier ^[3] ; Olivier,Dereure ^[4] ; Caroline,Dutriaux ^[5] ; Sophie,Dalac ^[6] ; Emilie,Scherrer ^[7] ; Laurie,Lévy-Bachelot ^[8] ; Laetitia,Verdoni ^[1] ; Gaëlle,Farge ^[1] ; Clara,Allayous ^[1] ; Bastien,Oriano ^[9] ; Stéphane,Dalle ^[9] ; Céleste,Lebbé ^[10]

作者单位： MSD France, Puteaux, France. ^[1] Current affiliation: Ividata Life Sciences, Levallois Perret, France. ^[2] Merck & Co., Inc., Kenilworth, NJ 07033, USA. ^[3] Department of Dermatology, CHRU de Lille, University of Lille, ONCO-THAI INSERM, Lille, U1189, France. ^[4] Department of Dermatology, University Hospital of Montpellier, Montpellier, France. ^[5] Department of Dermatology, Bordeaux Saint-André Hospital, Bordeaux, France. ^[6] Department of Dermatology, University Hospital of Dijon, Dijon, France. ^[7] MSD, London, UK. ^[8] Department of Dermatology, AP-HP Hôpital Saint Louis, F-75010 Paris, France. ^[9] Department of Dermatology, Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France. ^[10] Université de Paris, Department of Dermatology, AP-HP Hôpital Saint Louis, F-75010 Paris, France; INSERM U976. ^[11]

关键词 cohort study immunotherapy melanoma oncology pembrolizumab survival